Latest Breaking News On - Tropical disease priority review voucher program - Page 1 : comparemela.com

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1.

United kingdomUnited statesJoshua drummInstituto butantanFda tropical disease priority review voucher programExchange commissionDeerfield management companyGlobal communicationsTropical disease priority review voucher programUs centers for diseaseCoalition for epidemic preparedness innovationsUs advisory committee on immunization practicesThird partyValneva reports first quarterPriority review voucherEuronext paris

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Saint-Herblain , March 26, 2024 – Valneva SE , a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601,.

Hong kongSouth koreaUnited statesNew zealandRepublic of koreaJuan carlos jaramilloJoshua drummDynavax technologies corporationExchange commissionWorld health organizationAccess to advanced health instituteGlobal communicationsTropical disease priority review voucher programEuronext parisDrug administrationTropical disease priority review voucher

VALNEVA: Valneva Reports Full Year 2022 Results and Provides Corporate Updates

Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales

New zealandUnited kingdomUnited arab emiratesUnited statesKingdom of bahrainDeerfield orbimedInstituto butantanJoshua drummVivalis intercellTropical disease priority review voucher programVaccines announce european partnership for marketingGlobal communicationsDrug administrationEuropean commission for valneva inactivatedPan american health organizationEuropean medicines agency

Dr Anthony Fauci, Sens Sherrod Brown and Todd Young, and developers of pretomanid honored

At GHTC s Innovating for Impact Awards, Senators Sherrod Brown and Todd Young received Congressional Champion Awards, the developers of pretomanid and the BPaL regimen received the Partnership Award, and Dr. Anthony Fauci received the Lifetime of Service Award.

Mel spigelmanBarbara laughonTodd youngSherrod brownAnthony fauciJayshree rampiarNatasha bilimoriaNational institute of allergyTb drug development partnershipsUs national institutes for healthGlobal health technologies coalitionTropical disease priority review voucher programTb allianceNational action plan for combating multidrugLifetime of service awardPartnership award

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionTreasurervanda pharmaceuticals incOrphan drug designationDrug designationPriority review voucherInvestigational new drugTropical diseases